Navigation Links
Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
Date:12/5/2013

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Oppenheimer 24th Annual Healthcare Conference to be held at the Crown Plaza Hotel in New York City, December 10-11, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, Quizartinib, at 3:55 p.m. PT/ 12:55 p.m. ET on Wednesday, December 11th, 2013.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor pro
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
2. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
3. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
4. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
5. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
6. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
7. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
8. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
9. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
10. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
11. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 IRIDEX Corporation (NASDAQ: ... second quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, August 6, 2015 ... other business developments. Interested parties may access ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
(Date:7/30/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... regarding the notice it received on May 21, 2015 ... the Company was below certain of the Exchange,s continued ... 1101 of the NYSE MKT Company Guide, due to ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), today announced ... position of Chief Financial Officer. In this newly created position, ... company,s executive leadership team and lead the strategic direction ... Mr. Moskowitz joins Unigene after spending the previous ...
... 2012 Reportlinker.com announces that a new ... catalogue: Vaccines - ... This market research report package offers ... situation, trends and future outlook for vaccines ...
Cached Medicine Technology:Unigene Appoints David Moskowitz as Chief Financial Officer 2Unigene Appoints David Moskowitz as Chief Financial Officer 3Unigene Appoints David Moskowitz as Chief Financial Officer 4Unigene Appoints David Moskowitz as Chief Financial Officer 5Vaccines - Asia 2
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As more ... the activity of recruiting patients becomes a serious challenge. Because of growing competition, ... to patients within the local community. , The team at Wound Care ...
(Date:7/30/2015)... ... July 30, 2015 , ... Women's dating coach Simone Myers ... for women interested in improving their love lives using specific "lines" designed to ... to the public early this morning, has drawn praise from several dating and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. ... health care technology vendors, will take place May 14-17, 2016 in Minneapolis, MN. ...
(Date:7/30/2015)... , ... July 30, 2015 , ... 24/7 Care At ... Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) ... of home health care providers. 24/7 Care At Home’s agency is one of three ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3
... infected with a strain of bird flu that may prove to ... Yukol Limlaemthong on Monday. ,Yukol said, "There is a ... has had outbreaks before." ,Officials have said the ... the northern province of Pichit. This was one of seven "red ...
... blare out music loudly is at a 30 percent increased risk ... Research, UK, found that 14 to 16 year olds use their ... ,Over a third of the 1,000 people polled said they ... hearing, after listening to loud music. 28 percent of those polled ...
... of Bakers is opposing the compulsory addition of folic acid ... effect.// ,Folic acid addition in bread is made ... Tube Defects (NTD's), in babies by ensuring that women of ... said that compulsory fortification of bread will not have the ...
... A comprehensive testing programme for notifiable avian influenza has ... is free of the disease according// to Poultry Industry ... testing programme has tested the presence of highly pathogenic ... avian influenza through the testing blood samples from thousands ...
... after eating raw oysters from Puget Sound the Washington Department ... warning to consumers to completely avoid eating raw shellfish. ... consumption. But raw oysters may be prone to bacteria that ... The state has temporarily closed the Totten and Eld inlets ...
... Canadians returning to Ontario from Lebanon will not have to ... provincial government has said that it will waive the mandatory ... ,According to the Health Minister George Smitherman ... and will have access to the "health care they need ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: